For example, there is compelling evidence for the utility of PARP inhibitors in ovarian cancers in the absence of BRCA mutations (germline or somatic), presumably resulting from other molecular deficiencies in DNA repair. The gene discussed is PARP1; the disease is ovarian carcinoma.